Vera Therapeutics, Inc.

This study looks at the long-term safety and effects of atacicept in people with IgA nephropathy, a kidney disease. Participants have already completed a previous trial with atacicept. Researchers will monitor side effects and measure kidney function over time to see if the drug …

This study tests a drug called atacicept given once a month to people with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if monthly dosing lowers harmful antibodies and reduces protein in the urine, which are signs of kidney damage. About 9…

This phase 3 trial tests atacicept, a weekly injection, in 376 adults with IgA nephropathy (Berger's disease). The goal is to reduce protein in the urine and slow the loss of kidney function. Participants receive either atacicept or a placebo for about a year. The study is active…